Climate Change Data

PureTech Health plc

Climate Impact & Sustainability Data (2020)

Reporting Period: 2020

Environmental Metrics

Total Carbon Emissions:379.4 tCO2e (location-based); 379.5 tCO2e (market-based)
Scope 1 Emissions:25.9 tCO2e
Scope 2 Emissions:120.9 tCO2e
Scope 3 Emissions:232.7 tCO2e
Total Energy Consumption:638,505 kWh
Waste Generated:6,915 lbs (3,137 kg) hazardous waste; 5,567 lbs (2,525 kg) waste-to-energy
Carbon Intensity:1.05 tCO2e per FTE (location-based and market-based)

ESG Focus Areas

  • Patients
  • People
  • Planet
  • Governance

Environmental Achievements

  • Headquarters building is LEED Silver certified, using 35% less energy and generating 47% fewer greenhouse gas emissions than the AIA 2030 Challenge baseline.
  • Total market-based GHG emissions declined by -47% in 2020 vs 2018.

Social Achievements

  • 10% employee growth.
  • Provided up to 28 training hours per employee.
  • 50% of employees are women.
  • 36% of managers are women.
  • Provided lab supplies and PPE to local hospitals during the COVID-19 pandemic.

Governance Achievements

  • Established a standalone ESG committee.
  • Appointed Kiran Mazumdar-Shaw to the Board, increasing women representation to 37.5%.

Climate Goals & Targets

Short-term Goals:
  • Maintain or reduce GHG emissions per employee and per square meter of office space each year.

Environmental Challenges

  • Risks related to science and technology failure.
  • Risks related to clinical trial failure.
  • Risks related to regulatory approval.
  • Risks related to therapeutic safety.
  • Risks related to therapeutic profitability.
  • Risks related to intellectual property protection.
  • Risks related to enterprise profitability.
  • Risks related to hiring and retaining qualified employees.
  • Risks related to business, economic or public health disruptions.
Mitigation Strategies
  • Extensive due diligence before developing technology; capital-efficient approach; diversified model; Board oversight; expert network.
  • Diversified model; internal resources; external experts; preclinical experiments; quality vendors.
  • Experienced clinical managers and regulatory affairs professionals; high-quality protocols; reputable CROs; expert network.
  • Prioritizing safety in design; extensive preclinical and clinical trials; product liability insurance.
  • Reimbursement experts; monitoring competitive landscape; not all therapeutics rely on reimbursement.
  • Significant resources in patent prosecution and maintenance; in-house and external legal counsel; monitoring third-party patents; confidential disclosure agreements.
  • Significant cash reserves; relationships with investors and partners; Founded Entities' ability to raise funds.
  • Competitive compensation packages; extensive recruiting network; in-house recruiter; equity awards; benefits package; employee engagement efforts.
  • Proactive measures to limit on-site staff, require testing, and provide PPE.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: Companies Act 2006 (Strategic Report and Directors’ Reports) Regulations 2018, Greenhouse Gas Protocol

Certifications: LEED Silver

Third-party Assurance: Verco